News
-
26 May 2020
Immunocore announces dosing of first patient with fourth ImmTAC -
6 May 2020
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy -
4 March 2020
First Site in Global Uveal Melanoma Patient Registry Now Open -
2 March 2020
Immunocore Secures $130 Million Series B Financing -
9 December 2019
Immunocore announces dosing of first patient with third ImmTAC® bispecific -
11 November 2019
New Data Uncover Deeper Insight into Tebentafusp (IMCgp100) Clinical Activity in Patients with Advanced Melanoma, Including Uveal -
31 October 2019
Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference -
18 July 2019
Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma -
16 July 2019
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers -
3 June 2019
New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma